We profiled two IDH1 mutant glioma models, grown as intracranial xenografts, treated with an IDH1 inhbitor.  One model, BT424, was responsive to IDH1 inhibition by compound treatement and also displayed more transcriptional changes in response to treatment.  The other model, GB10, was not responsive to IDH1 inhibition and was transcriptionally quiet after treatment with compound. SOURCE: Diane Levitan (diane.levitan@merck.com) -  Merck

Pluto Bioinformatics

GSE105447: A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit